... PRGO. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. add_circle_outline. Trade type: Long stock, short call Stock: MJ Stock trade price: $20 Trade date: Feb 2 Option Expiry Date: February 19 Strike Price: $22 Premium Gained: $70 ââââââââââ-Stock price now: 29.08 Price to buy back option: $7.30. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. Perrigo has a ⦠As I understand it, I have made $200 on share appreciation, plus $70 selling the call for a total of $270. On average, they expect AbbVie's share price to reach $115.50 in the next twelve months. Perrigo Company PLC. This company and ⦠Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit Mar 01 / Zacks.com - Paid Partner Content Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus Plug Power, Inc. Plug Power Inc., an alternative energy technology provider, engages in the design, development, commercialization, and manufacture of fuel cell systems for the industrial off-road markets worldwide. Description. The companyâs shares closed last Friday at $42.10, close to its 52-week low of $40.01. Since 1887, Perrigo has been providing its customers and consumers with high-quality products that support personal health and wellness by delivering effective solutions that meet the needs of consumers. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. 4:03p How these teens are having fun in todayâs stock market, and, for the most part, making money 4:00p Forget Nio and XPeng. Their forecasts range from $24.00 to $53.00. ; Worldwide consumer Q4 ⦠See todayâs analyst top recommended stocks >> Perrigo Company (PRGO) In a report released yesterday, Elliot Wilbur from Raymond James maintained a Hold rating on Perrigo Company. According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -0.5% and a 47.4% success rate. 18 brokers have issued 1 year price targets for AbbVie's stock. A low P/E multiple is a good indication that the stock is undervalued. Their forecasts range from $95.00 to $140.00. At the current price of $41, PRGO stock hasnât gained at all since the March 2020 levels, while the broader S&P500 Index has rallied 72% over the same period. Perrigo is a leading global consumer-focused self-care company. View analysts' price targets for Pfizer or view top-rated stocks among Wall Street analysts. Our vision is to making lives better by bringing âQuality, Affordable Self-Care Productsâ that consumers trust everywhere they are sold.The Company is a leading provider of health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. This suggests a possible upside of 6.9% from the stock's current price. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. On average, they expect Pfizer's share price to reach $39.60 in the next twelve months. 1.51%. $41.57. This suggests a possible upside of 14.9% from the stock's current price. In a report issued on February 4, H.C. Wainwright also downgraded the stock to Hold with a $220.00 price target. Perrigo (PRGO +6.5%) Q4 consolidated net sales were $1.3B, a decrease of 2.5% vs. previous year, misses consensus by $40M. The stock presently has a consensus rating of âHoldâ and a consensus target price of $54.20. Perrigo Company (PRGO) In a report released yesterday, Elliot Wilbur from Raymond James maintained a Hold rating on Perrigo Company. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. NYSE PRGO opened at $43.90 on Wednesday. 81.96M USD.